Literature DB >> 7756094

Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

C H Wilder-Smith1, H U Bettschen, H S Merki.   

Abstract

1. Individual responses to intravenous boli of omeprazole have shown considerable variability. Data on the individual responses to the new omeprazole infusion formulation are lacking. 2. Individual dose-responses in the first 24 h of fixed-dose and pH-feedback-controlled infusions of omeprazole were assessed in two randomised, third-party blinded, cross-over studies, using two separate groups of eight healthy subjects. In study A, feedback-controlled infusions of omeprazole (target pH 5, dose range 0-12 mg h-1) and fixed-dose infusions (8 mg h-1) were compared, both with an initial bolus of 80 mg. Omeprazole plasma concentrations were measured. Study B assessed the effect on individual pH-control of a loading bolus of either 40 mg or 80 mg omeprazole, followed by feedback-controlled infusions. 3. Study A: the median % time of pH > 5 was 71.2 (total range: 48.9-83.2) with feedback infusions and 57.9 (28.0-95.3) with fixed-dose infusions (P = 0.06). The mean 24 h infusion doses were 173.1 mg (44.5-253.1) in the feedback group and 192 mg in the fixed-dose group. The AUC of omeprazole plasma concentrations ranged widely, but correlated with the % time of pH > 5 during fixed-dose infusions. Study B: initial boli of 40 mg and 80 mg of omeprazole resulted in similar 24 h median % of time with pH > 5, 69.2 (49.9-78.8) and 69.6 (44.4-87.7), respectively. Mean omeprazole doses infused by feedback pump were 187.6 mg (83.1-253.6) after 40 mg boli and 159.9 mg (61.8-227.0) after 80 mg boli.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756094      PMCID: PMC1364976          DOI: 10.1111/j.1365-2125.1995.tb04404.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Quantitative ultrastructural studies on inhibited and on partly stimulated gastric parietal cells.

Authors:  H F Helander; B I Hirschowitz
Journal:  Gastroenterology       Date:  1974-09       Impact factor: 22.682

2.  Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.

Authors:  J De Graef; M C Woussen-Colle
Journal:  Gastroenterology       Date:  1986-08       Impact factor: 22.682

3.  Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.

Authors:  H S Merki; F Halter; C H Wilder-Smith
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

4.  Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release.

Authors:  W Londong; V Londong; C Cederberg; H Steffen
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

5.  Circadian rhythm of gastric acid secretion in men with active duodenal ulcer.

Authors:  J G Moore; F Halberg
Journal:  Dig Dis Sci       Date:  1986-11       Impact factor: 3.199

6.  Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients.

Authors:  T Lind; M Moore; L Olbe
Journal:  Digestion       Date:  1986       Impact factor: 3.216

7.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

9.  Intravenous omeprazole rapidly raises intragastric pH.

Authors:  R P Walt; J R Reynolds; M J Langman; H L Smart; G Kitchingman; K W Somerville; C J Hawkey
Journal:  Gut       Date:  1985-09       Impact factor: 23.059

10.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.

Authors:  P J Prichard; N D Yeomans; G W Mihaly; D B Jones; P J Buckle; R A Smallwood; W J Louis
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

View more
  1 in total

1.  Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

Authors:  Jai Moo Shin; Nobuhiro Inatomi; Keith Munson; David Strugatsky; Elmira Tokhtaeva; Olga Vagin; George Sachs
Journal:  J Pharmacol Exp Ther       Date:  2011-08-09       Impact factor: 4.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.